Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
534.50    22.50 (4.39%)
Bid:
533.50
Ask:
534.50
Spread: 1.00 (0.187%)
Market Cap: £1.45b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

JBTDS Contract Award

Today 07:00

RNS Number : 4624K
Chemring Group PLC
01 July 2026
 

FOR IMMEDIATE RELEASE 1 JULY 2026

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

JBTDS FRP AWARD

 

Chemring is pleased to announce that its US subsidiary, Chemring Sensors & Electronic Systems ("CSES"), has been awarded a sole source Indefinite Delivery / Indefinite Quantity ("IDIQ") Full Rate Production ("FRP") contract for the Joint Biological Tactical Detection System ("JBTDS") Programme of Record. This three-year IDIQ, which was awarded by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense, has a current contract ceiling value of $48.8m and an estimated completion date of June 2029.

 

An initial production contract was also received with a value of $36.3m and a period of performance through to March 2028. Work under this contract will be performed at CSES's site in Charlotte, North Carolina.

 

The JBTDS system is an advanced sensor system that rapidly detects and identifies airborne biological warfare agents, and this award follows a period of successful field testing and acceptance trials with the US military.

 

Michael Ord, Group Chief Executive of Chemring, commented:

"For over two decades CSES has delivered mission-critical detection capabilities that protect the warfighter against complex and evolving biological threats, and we are delighted to receive this sole source contract in support of such a critical programme.

 

"This FRP award, which is the culmination of years of research and development, sits alongside our sole source position on the Enhanced Maritime Biological Detector programme for the US Navy, and positions Chemring as the market leader in the field of biological warfare agent detection."

 

-ENDS-

 

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Group 07584 142665

Ollie Hoare 07817 458804

 

Cautionary statement

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE-250 listed global business that specialises in the manufacture of high technology products and the provision of services to the defence, security and aerospace markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTWPUQAQUPQGAU
Date   Source Headline
31st Oct 20237:00 amRNSTransaction in Own Shares
30th Oct 20237:00 amRNSTransaction in Own Shares
27th Oct 20237:00 amRNSTransaction in Own Shares
26th Oct 20237:00 amRNSTransaction in Own Shares
25th Oct 20237:00 amRNSTransaction in Own Shares
24th Oct 20237:00 amRNSTransaction in Own Shares
23rd Oct 20237:00 amRNSTransaction in Own Shares
20th Oct 20237:00 amRNSTransaction in Own Shares
19th Oct 20237:00 amRNSTransaction in Own Shares
18th Oct 20237:00 amRNSTransaction in Own Shares
17th Oct 20237:00 amRNSUpdate on Countermeasure Deliveries
17th Oct 20237:00 amRNSTransaction in Own Shares
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSTransaction in Own Shares
12th Oct 20237:00 amRNSTransaction in Own Shares
11th Oct 20237:00 amRNSTransaction in Own Shares
10th Oct 20237:00 amRNSTransaction in Own Shares
9th Oct 20237:00 amRNSTransaction in Own Shares
6th Oct 20237:00 amRNSTransaction in Own Shares
5th Oct 20237:00 amRNSTransaction in Own Shares
4th Oct 20237:00 amRNSTransaction in Own Shares
3rd Oct 20232:28 pmRNSDirector/PDMR Shareholding
3rd Oct 20237:00 amRNSTransaction in Own Shares
2nd Oct 20231:56 pmRNSTotal Voting Rights
2nd Oct 20237:00 amRNSTransaction in Own Shares
29th Sep 20237:00 amRNSTransaction in Own Shares
28th Sep 20237:00 amRNSTransaction in Own Shares
27th Sep 20237:00 amRNSTransaction in Own Shares
26th Sep 20237:00 amRNSTransaction in Own Shares
25th Sep 20237:00 amRNSTransaction in Own Shares
22nd Sep 20237:00 amRNSTransaction in Own Shares
21st Sep 20237:00 amRNSTransaction in Own Shares
20th Sep 20237:00 amRNSTransaction in Own Shares
19th Sep 20237:00 amRNSTransaction in Own Shares
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSTransaction in Own Shares
14th Sep 20237:00 amRNSTransaction in Own Shares
13th Sep 20237:00 amRNSTransaction in Own Shares
12th Sep 20237:00 amRNSTrading update and contract wins
12th Sep 20237:00 amRNSTransaction in Own Shares
11th Sep 20237:00 amRNSTransaction in Own Shares
8th Sep 20237:00 amRNSTransaction in Own Shares
7th Sep 20237:00 amRNSTransaction in Own Shares
6th Sep 20237:00 amRNSTransaction in Own Shares
5th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 20237:00 amRNSTransaction in Own Shares
1st Sep 20231:04 pmRNSTotal Voting Rights
1st Sep 20237:00 amRNSTransaction in Own Shares
31st Aug 20237:00 amRNSTransaction in Own Shares
30th Aug 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.